. 2019 Feb 6;14(1):57–65. doi: 10.1007/s11523-019-00620-0

Table 4.

Investigator-assessed best confirmed response, by Response Evaluation Criteria In Solid Tumors version 1.1 (N = 21)

Response category	N (%)
Disease control^a	6 (29)
Objective response^b	1 (5)
Complete response	0
Partial response	1 (5)^c
Stable disease	5 (24)^d
Progressive disease	12 (57)
Not evaluable	1 (5)
Missing	2 (10)

^aDisease control defined as complete response, partial response, or stable disease

^bObjective response defined as complete response or partial response

^cPatient with gastric cancer (100 mg cohort)

^dPatients with urachus cancer (n =1), esophageal cancer (n =1) in the 50 mg cohort, and patients with meningioma (n =1), gastric cardia cancer (n =1), and intrahepatic bile duct cancer (n =1) in the 200 mg cohort